LANZO 30 mg rakeet oraalisuspensiota varten Suomi - suomi - Fimea (Suomen lääkevirasto)

lanzo 30 mg rakeet oraalisuspensiota varten

wyeth lederle nordiska ab - lansoprazolum - rakeet oraalisuspensiota varten - 30 mg - lansopratsoli

Mylotarg Euroopan unioni - suomi - EMA (European Medicines Agency)

mylotarg

wyeth europa ltd - gemtutsumab-ozogamisiini - leukemia, myeloidi, akuutti - antineoplastiset aineet - re-induktio hoito cd33-positiivisia aml aikuisten potilaiden ensimmäinen relapsivaihe, jotka eivät ole ehdokkaita muissa intensiivinen uudelleen induktio solunsalpaajahoito (e. korkea-annos ara-c) ja sen on täytettävä ainakin yksi seuraavista kriteereistä: kesto ensimmäisen remission 60 vuotta.

Comirnaty Euroopan unioni - suomi - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

METHOTREXATE  injektiokuiva-aine Suomi - suomi - Fimea (Suomen lääkevirasto)

methotrexate injektiokuiva-aine

wyeth-ayerst lederle inc american cyanamid company - methotrexatum natricum - injektiokuiva-aine - metotreksaatti

LEUCOVORIN 3 mg/ml injektioneste Suomi - suomi - Fimea (Suomen lääkevirasto)

leucovorin 3 mg/ml injektioneste

wyeth-ayerst lederle inc american cyanamid company - kalsium folinas - injektioneste - 3 mg/ml - kalsiumfolinaatti

METHOTREXATE 2.5 mg/ml injektioneste Suomi - suomi - Fimea (Suomen lääkevirasto)

methotrexate 2.5 mg/ml injektioneste

wyeth-ayerst lederle inc american cyanamid company - methotrexatum - injektioneste - 2.5 mg/ml - metotreksaatti

VANCOLED 500 mg infuusiokuiva-aine Suomi - suomi - Fimea (Suomen lääkevirasto)

vancoled 500 mg infuusiokuiva-aine

wyeth-ayerst lederle inc american cyanamid company - vancomycini hydrochloridum - infuusiokuiva-aine - 500 mg - vankomysiini

DIAMOX 250 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

diamox 250 mg tabletti

wyeth lederle nordiska ab - acetazolamidum - tabletti - 250 mg - asetatsolamidi

AUREOMYCIN 1 % silmävoide Suomi - suomi - Fimea (Suomen lääkevirasto)

aureomycin 1 % silmävoide

wyeth lederle nordiska ab - chlortetracyclini hydrochloridum - silmävoide - 1 % - klooritetrasykliini

LEDERMYCIN 300 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

ledermycin 300 mg tabletti

wyeth lederle nordiska ab - demeclocyclini hydrochloridum - tabletti - 300 mg - demeklosykliini